Patents by Inventor Eran Ophir

Eran Ophir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
    Publication number: 20240139318
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Application
    Filed: August 21, 2023
    Publication date: May 2, 2024
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • PVRL2 AND/OR PVRIG AS BIOMARKERS FOR TREATMENT
    Publication number: 20240103010
    Abstract: The present invention provides biomarkers for use in determining populations for treatment with anti-PVRIG antibodies and such biomarkers include, for example PVRIG and/or PVRL2 expression.
    Type: Application
    Filed: March 17, 2023
    Publication date: March 28, 2024
    Inventors: Roy Z. Granit, Gad S. Cojocaru, Eran Ophir, Amit Novik, Niv Sabath, Zoya Alteber
  • ANTI-PVRIG ANTIBODIES FORMULATIONS AND USES THEREOF
    Publication number: 20240082397
    Abstract: The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. The present invention is directed to monotherapy and combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.
    Type: Application
    Filed: January 28, 2022
    Publication date: March 14, 2024
    Inventors: Mark WHITE, Inbal BARBIRO, Ilan VAKNIN, Assaf WOOL, Zurit LEVINE, Henry Adeboye ADEWOYE, MD, Michael BUCKLEY, Jun LU, John HUNTER, Anat COHEN-DAYAG, Gad S. COJOCARU, Eran OPHIR, Zoya ALTEBER
  • COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS AND ANTI-PD-1 ANTIBODIES
    Publication number: 20240076373
    Abstract: The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. The present invention is directed to monotherapy and combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof. The present invention also provides biomarkers for use in determining populations for treatment with anti-PVRIG antibodies and such biomarkers include, for example PVRIG and/or PVRL2 expression.
    Type: Application
    Filed: January 28, 2022
    Publication date: March 7, 2024
    Inventors: Inbal BARBIRO, Ilan VAKNIN, Assaf WOOL, Zurit LEVINE, Paul A. BASCIANO, Brian D. LAMON, Henry Adeboye ADEWOYE, John HUNTER, Anat COHEN-DAYAG, Gad S. COJOCARU, Eran OPHIR, Zoya ALTEBER
  • ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
    Publication number: 20240075137
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Application
    Filed: May 23, 2023
    Publication date: March 7, 2024
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • Genetically modified anti-third party central memory T cells and use of same in immunotherapy
    Patent number: 11844827
    Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: December 19, 2023
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Noga Or-Geva, Eran Ophir, Yaki Eidelstein, Rotem Gidron Budovsky
  • PVRL2 AND/OR PVRIG AS BIOMARKERS FOR TREATMENT
    Publication number: 20230400467
    Abstract: The present invention provides biomarkers for use in determining populations for treatment with anti-PVRIG antibodies and such biomarkers include, for example PVRIG and/or PVRL2 expression.
    Type: Application
    Filed: October 26, 2021
    Publication date: December 14, 2023
    Inventors: Gad S. COJOCARU, Tal Fridman KFIR, Emmanuel WEYL, Amit NOVIK, Yossef KLIGER, Niv SABATH, Eran OPHIR, Zoya ALTEBER, Masha FRENKEL
  • COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS, ANTI-TIGIT ANTIBODIES, AND ANTI-PD-1 ANTIBODIES
    Publication number: 20230365680
    Abstract: The present invention is directed to combination treatments with anti-PVRIG antibodies, anti-TIGIT antibodies, and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.
    Type: Application
    Filed: September 30, 2021
    Publication date: November 16, 2023
    Inventors: Adeboye Henry ADEWOYE, MD, Inbal BARBIRO, Ilan VAKNIN, Eran OPHIR, Pierre FERRE
  • Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
    Patent number: 11701424
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: July 18, 2023
    Assignee: COMPUGEN LTD.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • TRIPLE COMBINATION ANTIBODY THERAPIES
    Publication number: 20230070685
    Abstract: The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 9, 2023
    Inventors: Spencer Liang, Ling Leung, Sarah Whelan, Maya Kotturi, Eran Ophir, Arthur Machlenkin, Zoya Alteber, Meir Azulay, Sandeep Kumar, Radhika Desai, Christopher Chan, Kathryn Logronio
  • ANTI-PVRIG AND ANTI-TIGIT ANTIBODIES FOR ENHANCED NK-CELL BASED TUMOR KILLING
    Publication number: 20230057899
    Abstract: Anti-PVRIG and anti-TIGIT for use in methods of treatment based on the enhanced NK-cell using the antibodies for the treatment of cancer.
    Type: Application
    Filed: December 7, 2020
    Publication date: February 23, 2023
    Inventors: Maya Kotturi, Sarah Whelan, Paul Neeson, Jessica Li, Joseph A. Trapani, Eran Ophir, Moran Galperin
  • ANTI THIRD PARTY CENTRAL MEMORY T CELLS, METHODS OF PRODUCING SAME AND USE OF SAME IN TRANSPLANTATION AND DISEASE TREATMENT
    Publication number: 20230024587
    Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.
    Type: Application
    Filed: May 3, 2022
    Publication date: January 26, 2023
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair REISNER, Yaki EIDELSTEIN, Eran OPHIR, Assaf LASK, Ran AFIK, Noga OR-GEVA, Esther BACHAR-LUSTIG
  • Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
    Patent number: 11324777
    Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: May 10, 2022
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Yaki Eidelstein, Eran Ophir, Assaf Lask, Ran Afik, Noga Or-Geva, Esther Bachar-Lustig
  • GENETICALLY MODIFIED ANTI-THIRD PARTY CENTRAL MEMORY T CELLS AND USE OF SAME IN IMMUNOTHERAPY
    Publication number: 20220080034
    Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.
    Type: Application
    Filed: November 22, 2021
    Publication date: March 17, 2022
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair REISNER, Noga OR-GEVA, Eran OPHIR, Yaki EIDELSTEIN, Rotem GIDRON BUDOVSKY
  • Triple combination antibody therapies
    Patent number: 11225523
    Abstract: The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: January 18, 2022
    Assignee: Compugen Ltd.
    Inventors: Spencer Liang, Ling Leung, Sarah Whelan, Maya Kotturi, Eran Ophir, Arthur Machlenkin, Zoya Alteber, Meir Azulay, Sandeep Kumar, Radhika Desai, Christopher Chan, Kathryn Logronio
  • Genetically modified anti-third party central memory T cells and use of same in immunotherapy
    Patent number: 11179448
    Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: November 23, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Noga Or-Geva, Eran Ophir, Yaki Eidelstein, Rotem Gidron Budovsky
  • Methods of transplantation and disease treatment
    Patent number: 10933124
    Abstract: A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, said anti-third party cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, wherein said cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: March 2, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Noga Or-Geva, Eran Ophir, Yaki Eidelstein, Rotem Gidron Budovsky
  • ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
    Publication number: 20210000952
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Application
    Filed: June 17, 2020
    Publication date: January 7, 2021
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
    Patent number: 10751415
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: August 25, 2020
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • Anti-TIGIT anibodies, anti-PVRIG antibodies and combinations thereof
    Patent number: 10213505
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: February 26, 2019
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall